Rite Aid (NYSE:RAD) has been one of the market's top-performing stocks over the past year. Shares have more than doubled as the pharmacy chain cut debt, closed stores, and launched its Wellness store format.

While Rite Aid's run has been impressive, a reduced earnings outlook released earlier this month cast doubt over whether the company can remain competitive against industry peers CVS Caremark (NYSE:CVS) and Walgreen (NASDAQ:WBA).

In the following slideshow, I highlight what investors should look for in Rite Aid's upcoming earnings release and raise some important questions that investors should be asking.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need to Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends CVS Caremark. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.